Spire Health
Winter 2015AcquiredRemote patient monitoring for lung disease patients.
Pressure-test this opportunity
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
Remote patient monitoring for lung disease patients.
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about Spire Health (W15).
Spire Health began in 2013 as a Stanford-born consumer wellness company selling a clip-on breathing tracker called the Spire Stone, then spent five years chasing a consumer market it never captured before pivoting to B2B remote patient monitoring for respiratory disease. The company raised $48.1M across four rounds, earned FDA clearance for its monitoring system in 2020, and published clinical data showing a 65% reduction in hospital admissions for COPD patients — yet was acquired by Wellinks in September 2024 in a non-cash transaction that valued the technology, not the company.[12][20]
The core failure was structural: Spire spent its formative years and early capital building a consumer wellness wearable in a market that was consolidating around Apple and Fitbit, then pivoted to a clinically validated B2B business that required hospital sales cycles, regulatory work, and capital intensity that its funding trajectory — a $38M Series B in 2021 followed by nothing — could not sustain. The company's own clinical success became its undoing: the COPD study that proved the product's value arrived in March 2023, just as the company was running out of runway and cycling through its third CEO in three years.[17][16]
The Wellinks acquisition was a salvage operation. Gilde Healthcare, Spire's majority investor, placed its partner Rich Wilmot on Wellinks' board as part of the deal — a signal that the investor was preserving the asset's value rather than betting on its standalone future.[21]
Image 1 / 2
Spire was founded in 2013 by Jonathan Palley, Neema Moraveji (Ph.D.), and Ben Yule, based on research conducted at Stanford University's Calming Technology Lab.[0] Moraveji, who holds a Ph.D. from Stanford, had spent years studying how technology could measure and influence physiological states like stress and focus. The founding team's mission was to make mindfulness measurable — to take the abstract concept of "calm" and turn it into a quantifiable, trackable signal.
The company entered Y Combinator's Winter 2015 batch, with a team of 52 and headquarters in San Francisco.[1] Its seed round closed on March 22, 2015, with Y Combinator participating.[30] The company was also backed by Rock Health and Stanford StartX, giving it credibility in both the consumer wellness and digital health worlds.[28]
The first product, Spire Stone, was a clip-on breathing tracker that measured respiratory patterns to infer stress and focus states. It grossed more than $8 million in sales — respectable for a niche wellness gadget, but a rounding error in a market where Fitbit was selling millions of devices per quarter.[2] A Stanford study presented at the Anxiety and Depression Association of America conference in February 2017 showed that Spire Stone use resulted in 37% more calm- and 25% more focus-related breathing patterns among LinkedIn employees — but this was a corporate wellness pilot, not a scalable business model.[3]
Palley articulated the company's consumer-era vision in November 2017: "To bring the (wearable) industry forward we had to make the wearable disappear."[6] That insight — that the device should be invisible — would eventually define the company's clinical pivot, but in 2017 it was still aimed at consumers.
The company's legal entity, SPIRE, INC., was incorporated on December 31, 2013, and had 40 employees as of December 31, 2020.[30]
Read the complete post-mortem, the rebuild playbook, and the exact reasons Spire Health is still worth studying now.